about
Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population studySerum vitamin D in patients with chronic obstructive lung disease does not correlate with mortality--results from a 10-year prospective cohort studyPlasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease.Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.Appropriate selection for omalizumab treatment in patients with severe asthma?Concurrent use of tramadol and oral vitamin K antagonists and the risk of excessive anticoagulation: a register-based nested case-control study.The effect of real-time teleconsultations between hospital-based nurses and patients with severe COPD discharged after an exacerbationImipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4*Interaction between tramadol and phenprocoumon[Use of alternative therapies among pediatric patients]Nurse tele-consultations with discharged COPD patients reduce early readmissions--an interventional studyScreening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease - a population-based database study[Successful implementation of pharmaceutical intervention at an acute medical admission unit]Efficacy of bronchial thermoplasty in patients with severe asthmaProtocol for a multicentre randomised controlled trial to investigate the effect on asthma-related quality of life from breathing retraining in patients with incomplete asthma control attending specialist care in Denmark
P50
Q31945955-0C56A5D3-1A9D-458B-85FD-7594CF2C4BA2Q34347507-BB821C06-A12B-4D0B-B7AA-AC8C44047643Q34558585-F1CC0663-B75F-4F03-97A5-174546E790FCQ35077055-0CB63752-E37B-4246-A32D-CD63651FAED7Q36053715-F5E1D3A6-180B-4A61-B889-416AA67250ECQ38621259-56299A69-5888-4380-BF92-5C2E3226D6DEQ43970773-10FDAC96-2023-4683-985B-E3EE6B5700D8Q57810897-65B337B5-B437-4AF8-8620-28944ED3C4B4Q60705900-A9EDC6A4-671C-41A8-AD2F-31BF10D19A64Q60705902-7EED6931-42CE-4B8A-A960-4B36C0DC36EBQ79295910-5FFE4D41-FEB7-458B-8E5F-578EB52F7366Q82893090-344585A6-2938-4E55-861D-F0061ABB2C21Q83364505-8F3CCEC3-0CAC-46F2-A53E-CE1E00A64133Q84077069-4C070AE5-A62F-4725-BB76-ED31807DD13EQ90589362-73FF51DC-2C66-4B51-81D6-C42A9A06A48EQ92356740-7CD75DE4-6C72-4F79-A14A-30ADE1319E1D
P50
description
researcher
@en
wetenschapper
@nl
name
H Madsen
@en
H Madsen
@nl
type
label
H Madsen
@en
H Madsen
@nl
prefLabel
H Madsen
@en
H Madsen
@nl
P106
P31
P496
0000-0002-2915-3161